ALLMedicine™ Thrombotic Thrombocytopenic Purpura Center
Research & Reviews 1,001 results
Annals of Hematology; Brown J, Potugari B et. al.
Aug 7th, 2022 - Pregnancy is a well-established trigger for a first episode or relapse of immune thrombotic thrombocytopenic purpura (iTTP). Other outcomes of subsequent pregnancy after a diagnosis of iTTP are less well described. We conducted this retrospective ...
Blood Advances; Pascual Izquierdo MC, Mingot-Castellano ME et. al.
Aug 6th, 2022 - Immune thrombotic thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy caused by anti-ADAMTS13 antibodies. Caplacizumab is approved for adults with an acute episode of iTTP in conjunction with PEX and immunosuppression. The objective of...
Orphanet Journal of Rare Diseases; Merlen C, Pépin E et. al.
Aug 5th, 2022 - Thrombotic microangiopathies (TMA) are serious medical conditions requiring a prompt diagnosis to adapt treatment. The determination of ADAMTS-13 activity enables discriminating thrombotic thrombocytopenic purpura (TTP) from other forms of TMA. Th...
BMJ Case Reports; Fang F, Tse B et. al.
Jul 29th, 2022 - Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease that may be triggered by inflammation, including infection or vaccination. Since the start of the COVID-19 pandemic, several case reports were published on de novo or relapsed...
Journal of Thrombosis and Haemostasis : JTH; Zheng L, Cao L et. al.
Jul 28th, 2022 - Severe deficiency of plasma ADAMTS13 activity may result in potentially fatal thrombotic thrombocytopenic purpura (TTP) and relative deficiency of plasma ADAMTS13 activity may be associated with adverse outcomes of certain malignancies. Here, we r...
Guidelines 1 results
British Journal of Haematology; Scully M, Hunt BJ et. al.
May 26th, 2012 - Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies.|2012|Scully M,Hunt BJ,Benjamin S,Liesner R,Rose P,|diagnosis,pathology,therapy,diagnosis,pathology,therapy,
Drugs 45 results see all →
Clinicaltrials.gov 41 results
Jul 21st, 2022 - The anticipated study duration per participant with the presenting episode therefore is a maximum of about 24 weeks (ie, 1 day of screening + maximum 12 weeks of treatment for the presenting episode + 12 weeks of follow-up).
Jul 7th, 2022 - The investigators will conduct a prospective cohort study at the London Health Sciences Centre, Ontario, Canada. The investigators will identify 15-30 idiopathic thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome patients w...
Jun 14th, 2022 - Systemic lupus erythematosus (SLE) is a systemic heterogeneous autoimmune disease with a highly variable course and prognosis that many different organs may be affected . It has wide spectrum of clinical presentation that affects all ages and ethn...
May 27th, 2022 - The lack of ADAMTS13 is the only biological marker that is specific for aTTP diagnosis8 and the assessment of ADAMTS13 is of clinical importance because it is essential for the rapid differential diagnosis between aTTP and other TMA. Furthermore, ...
May 24th, 2022 - 1.) Identification of predictive markers for morbidity and mortality in acute TTP and in TTP relapses using a prospective long-term registry and 2.) Investigation of the pathophysiological processes in acute bouts and in remission by recording the...
News 94 results
Oct 6th, 2021 - We recently traveled to Seattle, California for an OncLive® State of the Science Summit™ on Hematologic Malignancies. At the meeting, faculty from Seattle Cancer Care Alliance provided insight on current and evolving standards of care in leukemia,...
Oday Elmanaseer, MD (email@example.com), Alzira Avelino, MD et. al.
Sep 9th, 2021 - Introduction Epstein-Barr virus (EBV) is a herpes virus that commonly causes infectious mononucleosis (IM) and linked to different hematological conditions. Here we present a case of EBV-triggered Hemolytic Uremic Syndrome (HUS) with pulmonary inv.
Jul 22nd, 2021 - Transplant-associated thrombotic microangiopathy (TA-TMA) is a complication of stem cell transplants that can occur with peripherally mobilized stem cells or bone marrow-derived stem cells. TA-TMA remains a difficult complication to address, with ...
Apr 8th, 2021 - Samer Khaled, MD: That is a good segue to our next segment about the challenges of a prompt and accurate diagnosis of TA-TMA [transplant-associated thrombotic microangiopathy]. One of the challenges is to identify TA-TMA early in the course of the...
Mark S. Lesney, PhD
Apr 7th, 2021 - Real-world data for caplacizumab outcomes matched those seen in randomized controlled trials (RCTs) for the treatment of immune-mediated thrombotic thrombocytopenic purpura (iTTP), according to the results of a retrospective study. Data collected.